It has been discovered that CD34 neg cells, for example HSPCs, can be modified to increase their ability to migrate and to engraft in bone marrow. One embodiment provides a method for modifying CD34 neg cells by using glycosyltransferase-programmed stereosubstitution (GPS) to create relevant selectin-binding glycan determinants on the cell surface. For example, the CD34 neg cells can be treated with a fucosyltransferase, such as an α(1,3)-linkage-specific fucosyltransferase. Representative enzymes that can be used include, but are not limited to fucosyltransferase VI (FTVI or FucT-6) or fucosyltransferase VII (FTVII of FucT-7). These enzymes specifically places a fucose onto a terminal type 2-lactosamine unit; if that lactosamine is capped with an α(2,3)-linked sialic acid, sLe x is created.
|Original language||English (US)|
|State||Published - Sep 27 2018|